Vir Biotechnology, Inc. (VIR)

Market Cap	796.25M
Revenue (ttm)	20.86M
Net Income (ttm)	-577.65M
Shares Out	138.24M
EPS (ttm)	-4.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	713,230
Open	5.79
Previous Close	5.85
Day's Range	5.70 - 5.89
52-Week Range	4.32 - 14.45
Beta	1.22
Analysts	Strong Buy
Price Target	30.25 (+425.17%)
Earnings Date	Aug 4, 2025

About VIR

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 11, 2019
• Employees: 408
• Stock Exchange: NASDAQ
• Ticker Symbol: VIR
• Website: https://www.vir.bio

Financial Performance

In 2024, Vir Biotechnology's revenue was $74.21 million, a decrease of -13.90% compared to the previous year's $86.18 million. Losses were -$521.96 million, -15.14% less than in 2023.

Analyst Summary

According to 8 analysts, the average rating for VIR stock is "Strong Buy." The 12-month stock price target is $30.25, which is an increase of 425.17% from the latest price.

Price Target

$30.25

(425.17% upside)

Analyst Consensus: Strong Buy